EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening

Satoko Ito, Rosa M Xicola, Manraj Sra, Kunal C Potnis, Vinit Singh, Peter Gershkovich, Edward Stites, Joanna Gibson, Harlan M Krumholz, Xavier Llor, George Goshua

Clinical Gastroenterology and Hepatology · 2025-11 · 23 (12) · 2328-2338.e9

DOI: 10.1016/j.cgh.2025.03.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-11. Verfasst von Satoko Ito und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Colorectal Neoplasms, Hereditary Nonpolyposis, Early Detection of Cancer, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NOMIS Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Testing all colorectal cancers (CRCs) for mismatch repair status to evaluate for Lynch syndrome (LS) has been recommended for years. Owing to attrition in the multistep diagnostic testing pathway, most qualifying patients still do not receive genetic testing for LS. This leads to missed diagnoses and preventable cancer incidence. To tackle this, we previously reported a systems approach that resulted in a dramatic increase in the identification of patients with LS. We aim to evaluate the cost-effectiveness of this intervention compared with both real-world pre-intervention experience and with upfront germline testing of all CRC probands. METHODS: We employed data from the Prospective Lynch Syndrome Database, the National Cancer Institute Surveillance, Epidemiology, and End Results program, and pre-/post-intervention cohort studies to build lifetime Markov cohorts of CRC probands, testing 3 strategies: (1) current standard-of-care; (2) optimized standard-of-care; and (3) upfront germline testing. The primary outcome was the incremental cost-effectiveness ratio (ICER) in $ per quality-adjusted life-year (QALY) from the United States health system perspective. RESULTS: Strategies #1 to #3 accrued 11.97, 11.98, and 11.99 discounted QALYs at discounted costs of $100,610, $100,980, and $102,290, respectively. The pairwise ICERs on the frontier were $34,500/QALY (95% credible interval [CI], $28,400-$44,200) and $98,500/QALY (95% CI, $73,700-$216,000), respectively. The cost-effectiveness of #3 vs #1 was $70,300/QALY (95% CI, $54,600-$92,500). Current standard-of-care was favored in 0.0% of 10,000 Monte Carlo iterations. CONCLUSIONS: Current clinical practice is cost-ineffective. Prospective intervention to dramatically increase LS testing (ie, to reach a threshold of >75%) or, if this level cannot be reached, upfront germline testing are cost-effective interventions that improve quality-adjusted life expectancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisColorectal Neoplasms, Hereditary NonpolyposisEarly Detection of CancerColorectal NeoplasmsGenetic TestingMass ScreeningHumansMaleMiddle AgedFemaleAdultAgedUnited StatesProspective Studies

Stichwörter der Autor:innen

Colorectal CancerCost-effectivenessDiagnosisLynch Syndrome

Autor:innen und Institutionen

  • Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.
  • Department of Genetics, Yale School of Medicine, New Haven, Connecticut.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • NOMIS Stiftung
  • Frederick A. DeLuca Foundation
  • NHLBI
  • Yale Cancer Center
  • National Institutes of Health
  • NCI

Zitieren

APA

Ito, S., Xicola, R. M., Sra, M., Potnis, K. C., Singh, V., Gershkovich, P., Stites, E., Gibson, J., Krumholz, H. M., Llor, X., & Goshua, G. (2025). Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology and Hepatology, 23(12), 2328-2338.e9. https://doi.org/10.1016/j.cgh.2025.03.006

Vancouver

Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, et al. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology and Hepatology. 2025;23(12):2328-2338.e9. doi:10.1016/j.cgh.2025.03.006

BibTeX
@article{Ito2025,
  author = {Ito, Satoko and Xicola, Rosa M and Sra, Manraj and Potnis, Kunal C and Singh, Vinit and Gershkovich, Peter and Stites, Edward and Gibson, Joanna and Krumholz, Harlan M and Llor, Xavier and Goshua, George},
  title = {Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {12},
  pages = {2328--2338.e9},
  doi = {10.1016/j.cgh.2025.03.006}
}
Kostenlos starten →